TY - JOUR
T1 - Factor VIII products and inhibitor development in severe hemophilia A
AU - Gouw, Samantha C.
AU - Van Der Bom, Johanna G.
AU - Ljung, Rolf
AU - Escuriola, Carmen
AU - Cid, Ana R.
AU - Claeyssens-Donadel, Ségolène
AU - Van Geet, Christel
AU - Kenet, Gili
AU - Mäkipernaa, Anne
AU - Molinari, Angelo Claudio
AU - Muntean, Wolfgang
AU - Kobelt, Rainer
AU - Rivard, George
AU - Santagostino, Elena
AU - Thomas, Angela
AU - Van Den Berg, H. Marijke
PY - 2013/1/17
Y1 - 2013/1/17
N2 - BACKGROUND: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). METHODS: We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity,
AB - BACKGROUND: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). METHODS: We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity,
UR - http://www.scopus.com/inward/record.url?scp=84872450786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872450786&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1208024
DO - 10.1056/NEJMoa1208024
M3 - Article
C2 - 23323899
AN - SCOPUS:84872450786
VL - 368
SP - 231
EP - 239
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 3
ER -